Atopic Dermatitis Resources
Midwest Allergy Sinus Asthma, SCAtopic Dermatitis is the most common form of eczema and is a chronic condition. Symptoms of atopic dermatitis include, but are not limited to, itchiness, redness, rash, dry/scaly skin, and open/crusted/weepy sores. If the skin becomes infected, it may form a yellowed crust or pus-filled bumps. The skin may also become thicker and calloused from excessive scratching and rubbing.
It is estimated that more than 18 million adults in the United States have atopic dermatitis. Children tend to develop the condition either in infancy or early childhood, but the condition can appear at any time in a person’s life. Those who come from families with a history of atopic dermatitis, asthma, or hay fever are at greater risk of developing this condition.
Seek medical treatment and advice from your doctor if you suspect you may have this condition.
Other ressources:
Related Articles:
AD Study
If your child have atopic dermatitis and is between 6-7 years old, contact us to learn more about the study of an investigational cream.
Clinical Trial: Moderate to Severe Eczema/Atopic Dermatitis (Rocket-Horizon) – CLOSED
(Enrollment Closed) Are you 18 years old and above? Have you had moderate to severe Eczema/Atopic Dermatitis for at least three years? Have you tried Topical Corticosteroid over the past 12 months but it did not work? We accept participants of all sexes. You may be...
Clinical Trial: Call for Moderate-Severe Eczema Patients (SIGNAL-AD) – CLOSED
We are looking for people with moderate to severe eczema who are 18 years old or above to participate in a study. The patient will be paid while getting close care and monitoring by doctors you know.
Great News: Positive Top-Line Result for Safety and Efficacy of a Non-Steroidal Topical Treatment for Atopic Dermatitis in Children (MASA SWIA)
On July 11, 2023, MASA’s research team at Sneeze Wheeze and Itch Associates received great news regarding the positive top-line research results on the safety and efficacy of a non-steroidal topical treatment for Atopic Dermatitis (AD) in children. The SWIA research team, led by Dr. Siri as Principal Investigator, contributed to the pivotal Phase 3 study for ruxolitinib cream, along with 98 other research centers worldwide!
